233775-20-7

Basic information

• Product Name: 7-amino-4-ethyl-2H-1,4-benzoxazin-3(4H)-one(SALTDATA: HCl)
• Synonyms: 7-amino-4-ethyl-2H-1,4-benzoxazin-3(4H)-one(SALTDATA: HCl);7-amino-4-ethyl-3,4-dihydro-2H-1,4-benzoxazin-3-one
• CAS NO: 233775-20-7
• Molecular Formula: C₁₀H₁₂N₂O₂
• Molecular Weight: 192.21448
• Mol File: 233775-20-7.mol

Chemical Properties

• Boiling Point: 483.5±45.0 °C(Predicted)
• Appearance: /
• Density: 1.242±0.06 g/cm3(Predicted)
• PKA: 4.74±0.20(Predicted)
• CAS DataBase Reference: 7-amino-4-ethyl-2H-1,4-benzoxazin-3(4H)-one(SALTDATA: HCl)(CAS DataBase Reference)
• NIST Chemistry Reference: 7-amino-4-ethyl-2H-1,4-benzoxazin-3(4H)-one(SALTDATA: HCl)(233775-20-7)
• EPA Substance Registry System: 7-amino-4-ethyl-2H-1,4-benzoxazin-3(4H)-one(SALTDATA: HCl)(233775-20-7)

Safety Data

• Hazardous Substances Data: 233775-20-7(Hazardous Substances Data)

Upstream product

• 81721-86-0 7-nitro-4H-benzo[1,4]oxazin-3-one 
• 233775-19-4 4-ethyl-7-nitro-2H-benzo[b][1,4]oxazin-3(4H)-one 

Relevant articles and documents

Rational Design, Synthesis, and Biological Activity of N-(1,4-Benzoxazinone)Acetamide Derivatives as Potent Platelet Aggregation Inhibitors

Inappropriate thrombus formation within blood vessels is the leading cause of mortality in the industrialized world. Platelet aggregation activated by thrombin may have close relationship with thrombosis. Based on our studies on the pharmacophoric role of 1,4-benzoxazine-3(4H)-one for desirable platelet aggregation inhibitory activity, we identified N-(4-ethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-2-(4-methylpiperazin-1-yl)acetamide (BOAP-AM6) and N-(4-butyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-2-(4-(4-fluorophenyl)piperazin-1-yl)acetamide (BOAP-AM21) as platelet aggregation inhibitors with an IC50 of 8.93 and 8.67 μM, respectively, as potent as the positive control aspirin. A combination of structure–activity relationships studies and molecular modeling revealed that the molecule BOAP-AM6 interacted with the amino acid residue TYR166 and ARG214 in the binding site of GPIIb/IIIa receptor through hydrogen bond and compound BOAP-AM21 acted on the amino acid residue ASN215 and ALA218, both through the same approach as the reported potent molecules 7a and 7b.

HETEROCYCLIC COMPOUND

The present invention provides a heterocyclic compound having an RORγt inhibitory action. The present invention relates to a compound represented by the formula (I): wherein Ar is a the partial structure (1) to the partial structure (5), Q is a bivalent group selected from the group consisting of (Ia)-(If), and B is a ring optinally having substituent(s), or a salt thereof.

FUSED IMIDAZOLE COMPOUNDS

The present invention provides compounds represented by formula (I), pharmaceutically acceptable salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof (wherein the characters are as defined in the description). The compounds represented by formula (I) have affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 (GABAA α5) and act as GABAA α5 negative allosteric modulators (GABAA α5 NAM), so that they are useful in the prevention and/or treatment of diseases which are related to the GABAA α5 such as Alzheimer's disease.

ROR-GAMMA MODULATORS AND USES THEREOF

The present invention relates to a compound of formula I, or an isotopic form, stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate, a polymorph, a prodrug, N-oxide or S-oxide thereof; and processes for their preparation. The invention further relates to pharmaceutical compositions containing the compounds and their use in the treatment of diseases or disorders mediated by RORγ.

Pentacyclic kinase inhibitors

The invention provides novel kinase inhibitors that are useful as therapeutic agents for example in the treatment malignancies where the compounds have the general formula I wherein A, X, Y, Z, Ra, Rb, Rc, R1, R2, R3 and m are defined herein.